AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy
Summary : The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending…
Summary : The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending…
Summary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
Summary : Alembic Pharmaceuticals received a tentative approval from the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug…
People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19,…
Synopsis : Nanomedicines – typically drugs hidden within nanoscopic fatty membranes (‘liposomes’) – have potential to transform chemotherapy treatments, improving drug delivery…
Synopsis : Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in…
Summary : Pre-specified secondary endpoint showed 0-11 vaccine to placebo case split for medically attended C. difficile infection (CDI), corresponding to 100%…
Summary : A new study has found that artificial intelligence (AI) apps helped protect small and medium-sized businesses against many of the…
Summary : It’s an understatement to note that the bottom lines for Moderna and Pfizer have been fattened by the success of…
Summary : The U.S. Food and Drug Administration turned down Ocugen’s Emergency Use Authorization (EUA) request for Covaxin in children 2 to…